Docstoc

Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study

Document Sample
Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study Powered By Docstoc
					
				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:0
posted:2/4/2013
language:Unknown
pages:2
Description: JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients with hematological malignancies such as leukemia and lymphoma. The primary endpoint is defined as the rate of mortality (%) within 100 days after transplantation. For the final analysis, the historical co a style=
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.